Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 13, 2013. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 638,000 Ordinary Shares of 25 pence each.
- Purchase Price Range: High of 1,573.00 pence; Low of 1,560.00 pence per share.
- Treasury Holdings (Settled): 516,022,909 shares (9.61% of total issued share capital).
- Treasury Holdings (Including Unsettled): 517,256,909 shares (10.65% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,855,860,179 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 638,000 shares on December 13, 2013. These shares are intended to be held in Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.65% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (4,855,860,179) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of voting rights held in Treasury (10.65% including unsettled shares).
- Review the price paid per share (1,560.00 to 1,573.00 pence) against market prices on December 13, 2013.
- Note that this filing does not contain operational or financial performance data for the period.